You are here

eplontersen

AstraZeneca adds Latin America to Ionis ATTR partnership for $20M

Fierce Biotech

Fri, 07/28/23 - 11:48 am

Ionis Pharmaceuticals

Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam

Fierce Biotech

Mon, 04/24/23 - 10:26 am

Ionis Pharmaceuticals

Could This Rare-Disease Drug Candidate Become a Blockbuster?

Motley Fool

Wed, 04/19/23 - 10:26 am

Ionis Pharmaceuticals

ATTR amyloidosis

Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy

PR Newswire

Wed, 03/8/23 - 09:47 am

Ionis Pharmaceuticals

AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen

Pharmaforum

Tue, 06/21/22 - 10:57 am

AstraZeneca, Ionis close deal on antisense therapy development

Pharmaceutical Business Review

Thu, 12/30/21 - 11:07 am

Ionis Pharmaceuticals

AstraZeneca wagers $200M on Ionis' next chance at a rare disease drug

BioPharma Dive

Tue, 12/7/21 - 10:48 am

Ionis Pharmaceuticals

transthyretin amyloidosis